Sirona Biochem (Seite 3100)

[Jon_Schnee]

Zitat von Jon_Schnee: Gestern Company per Mail angeschrieben. Antwort nach 5 Stunden. Das nenn ich mal Aktionär freundlich

Hier mal die Frage:

Dear All

I am shareholder.
Congratulation, very good deal!

Could you tell me when do you get the first milestone payment & what is the value of it?

Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

And how long are you funded without this deal?

best regards
xxxxxxxxxxxxx

Antwort:


Hi xxxxx,

Thank you for your message.

I'm sorry but the information included in the news release is all that we are making public regarding the terms of the agreement.

What may be valuable to note however is that Wanbang Pharma will be paying for all future studies towards clinical approval of our SGLT2 Inhibitor. With each new piece of data created by Wanbang, the value of our compound grows exponentially for the rest of the world. We know that previous SGLT2 compounds acheiving success in phase 2 and 3 have earned transaction fees in the hundreds of millions of dollars.

Sirona will not assume any financial risk or resource burden in the future studies, while enjoying the all of the value created by Wanbang's very capable development teams. We couldn't be more excited about the future for this compound.

Currently we have roughly two months in the bank and we remain focused on executing our business plan and creating significant value for our shareholders.

Thank you again for your interest.



Antonia Issa, BA, MBA
Communications Manager

[e-mail]

D 604.282.6065



Sirona Biochem Corp.

605-889 West Pender Street

Vancouver, BC V6C 3B2

M 604.641.4466

F 604.608.5471

TF 1.888.SIRONA1 (7476221)



TSX-V: SBM

www.sironabiochem.com

[Jon_Schnee]

Gestern Company per Mail angeschrieben. Antwort nach 5 Stunden. Das nenn ich mal Aktionär freundlich

Hier mal die Frage:

Dear All

I am shareholder.
Congratulation, very good deal!

Could you tell me when do you get the first milestone payment & what is the value of it?

Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

And how long are you funded without this deal?

best regards
xxxxxxxxxxxxx

[Jon_Schnee]

gutes Posting -> SH:
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…

I was starting to have my doubts that this company would actually be able to close any deals that generated revenue. I think we are all starting to see the possibilities a bit mroe clearly now.

I'm especially pleasantly surprised that the first deal seems to reveal a very cleaver strategy. I had assumed that Sirona would just license the SGLT2 inhibitor out at a pre-clinical stage, which means the value would be fairly limited compared to a drug already in clinical trials. The Wanbang/Fosun deal suggests a much more ambitious plan, where the deal generates clinical trial data that adds a whole lot of value to the SGLT2 inhibitor. In effect, Sirona traded the rights in China for a modest amount of money plus the possibility of clinical trial data that could make the product worth $100 million or more. We would never have gotten a deal like that from big pharma.

From FierceBiotech:

"Meanwhile, China's Shanghai Fosun Pharmaceutical is coming on strong for next year, Forbes says. Controlled by Chinese billionaire Guo Guangchang, the company has been snapping up stakes in other drugmakers and setting up joint ventures with the likes of Lonza."

http://www.fiercepharma.com/story/csl-sun-pharma-rank-absolu…

[Jon_Schnee]

Bei Stockhouse.com wird Sirona im Gegensatz zu hier disktutiert:
http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…

[Jon_Schnee]

So viel zu den unqualifizierten Postings

Zitat von Datteljongleur: Sehr beeindruckend. Echt.


Scheint gerade der neueste "Trend" zu sein, diese Art von Klitschen zu pushen.

Zitat von VanGillen: Ergebnis/Aktie (in EUR) n.a. n.a. n.a.
KGV n.a. n.a. n.a.
Dividende/Aktie (in EUR) n.a. n.a. n.a.
Dividendenrendite (in %) n.a. n.a. n.a.
Sehr beeindruckend. Echt.

Zitat von nordlicht100: Ich möchte mal wissen, wie risikobereit (oder verzweifelt?!) man eigentlich sein muss, um solche Aktien zu kaufen!

Ich meine, die Dinger kann man ja eigentlich nicht mal mehr als Penny-Stock begreifen.

[Jon_Schnee]

Antwort auf Beitrag Nr.: 45.278.759 von Jon_Schnee am 19.08.13 16:36:42

PS. Der China Partner ist Klasse

About Wanbang Pharma
Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.

[Jon_Schnee]

Zitat von Jon_Schnee: Was ist der Deal Wert? US$9.5M & Royalties:
Nicht schlecht für eine Marktkapitalisierung von US$15M

In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

Und der Deal ist "nur" auf China beschränkt. Weiter SGLT2 Inhibitor Deals können jederzeit noch kommen.

Ich warte aber vorallem auf den Skin Lightening Deal hier geht dann richtig die Post ab.

[Jon_Schnee]

Antwort auf Beitrag Nr.: 45.278.593 von Jon_Schnee am 19.08.13 16:14:31

Was ist der Deal Wert? US$9.5M & Royalties:
Nicht schlecht für eine Marktkapitalisierung von US$15M

In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

[Jon_Schnee]

Sirona Biochem Signs LOI with China’s #1 Ranked Anti-Diabetic Company, Wanbang Pharma

http://www.sironabiochem.com/sirona-biochem-signs-loi-with-c…

Vancouver, British Columbia – August 19, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona’s SGLT2 Inhibitor in the People’s Republic of China (PRC). In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

Under the terms of the LOI, Wanbang Pharma will assume responsibility for funding and leading all clinical studies required for Chinese Food and Drug Administration approval. Sirona Biochem will be provided all clinical study results to support new regulatory applications outside of PRC.

“We are excited by the opportunity to work with Wanbang Pharma, the leading anti-diabetic company supplying the largest diabetic population in the world,” said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “With more than 90 million people suffering from diabetes in China and the market growing more than 20% per year, we believe that Wanbang Pharma is uniquely positioned to provide maximum potential to commercialize our SGLT2 Inhibitor in the Chinese marketplace”.


About Wanbang Pharma

Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.

Wanbang Pharma is a subsidiary of Fosun Pharmaceutical Group which is listed on the Shanghai Stock Exchange (SHA:600196). Fosun Pharma, a major shareholder of Sino Pharma (HKG:1099), the largest drug distributor in China, is part of the Fosun Group, the largest non-state owned enterprise group in China which is listed on the Hong Kong stock exchange (HKG:0656).


About Sirona Biochem

Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: [phone]
Email: [e-mail]

[Jon_Schnee]

Skin whitening Market ist riesig. Immer mehr Produkte werden in verschieden Länder verbannt, da Giftig. Hier schlägt die Stunde von Sirona Biochem. Aber sie brauchen einen oder mehrere starke Partner für Produktion, Vertrieb und vor allem Marketing/Werbung.

BBC News Skin whitening in Asia Magic potion or poison
http://www.youtube.com/watch?v=PSvRegwln5Q